HIV drug repurposed in fight against early Alzheimer's
NCT ID NCT06519357
Summary
This small, early-stage study is testing whether lamivudine, a drug used for HIV, can lower levels of specific proteins in the blood that are linked to brain changes in Alzheimer's disease. The study involves 23 older adults with mild cognitive impairment who show early signs of Alzheimer's. Participants take the drug for 24 weeks so researchers can measure changes in these protein levels and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Germans Trias I Pujol Hospital
Badalona, BARCELONA, 08916, Spain
Conditions
Explore the condition pages connected to this study.